Loading clinical trials...
Loading clinical trials...
A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors
Conditions
Interventions
LY3039478
Taladegib
+5 more
Locations
11
United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Rigshospitalet
Copenhagen, København Ø, Denmark
Institut Bergonie
Bordeaux, France
Start Date
November 4, 2016
Primary Completion Date
August 9, 2018
Completion Date
February 13, 2020
Last Updated
August 21, 2025
NCT07489378
NCT07547774
NCT07040891
NCT07181681
NCT06257264
NCT07360314
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions